NO973814L - Basisk stabilisert sammensetning av HMG-CoA-reduktase inhibitor - Google Patents

Basisk stabilisert sammensetning av HMG-CoA-reduktase inhibitor

Info

Publication number
NO973814L
NO973814L NO973814A NO973814A NO973814L NO 973814 L NO973814 L NO 973814L NO 973814 A NO973814 A NO 973814A NO 973814 A NO973814 A NO 973814A NO 973814 L NO973814 L NO 973814L
Authority
NO
Norway
Prior art keywords
hmg
coa reductase
reductase inhibitor
stabilized composition
basic stabilized
Prior art date
Application number
NO973814A
Other languages
English (en)
Other versions
NO973814D0 (no
NO316724B1 (no
Inventor
Toyojiro Muramatsu
Katsumi Mashita
Yasuo Shinoda
Hironori Sassa
Hiroyuki Kawashima
Yoshio Tanizawa
Hideatsu Takeuchi
Original Assignee
Kowa Co
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co, Nissan Chemical Ind Ltd filed Critical Kowa Co
Publication of NO973814D0 publication Critical patent/NO973814D0/no
Publication of NO973814L publication Critical patent/NO973814L/no
Publication of NO316724B1 publication Critical patent/NO316724B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19973814A 1995-12-22 1997-08-19 Basisk stabilisert sammensetning av HMG-CoA-reduktase inhibitor NO316724B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP35465495 1995-12-22
PCT/JP1996/003722 WO1997023200A1 (en) 1995-12-22 1996-12-20 Pharmaceutical composition stabilized with a basic agent

Publications (3)

Publication Number Publication Date
NO973814D0 NO973814D0 (no) 1997-08-19
NO973814L true NO973814L (no) 1997-10-13
NO316724B1 NO316724B1 (no) 2004-04-19

Family

ID=18439011

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19973814A NO316724B1 (no) 1995-12-22 1997-08-19 Basisk stabilisert sammensetning av HMG-CoA-reduktase inhibitor
NO2011006C NO2011006I2 (no) 1995-12-22 2011-05-04 Pitavastatin, valgfritt i form av av farmasøytisk akseptabelt salt eller ester

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2011006C NO2011006I2 (no) 1995-12-22 2011-05-04 Pitavastatin, valgfritt i form av av farmasøytisk akseptabelt salt eller ester

Country Status (26)

Country Link
EP (1) EP0814782B1 (no)
JP (1) JP3276962B2 (no)
KR (1) KR100348842B1 (no)
CN (1) CN1137684C (no)
AT (1) ATE228354T1 (no)
AU (1) AU725622B2 (no)
CA (1) CA2213608C (no)
CZ (1) CZ288545B6 (no)
DE (2) DE69625046T2 (no)
DK (1) DK0814782T3 (no)
ES (1) ES2183023T3 (no)
FR (1) FR11C0007I2 (no)
HU (1) HU227798B1 (no)
IL (1) IL121565A (no)
MX (1) MX9706389A (no)
NO (2) NO316724B1 (no)
NZ (1) NZ324446A (no)
PL (1) PL186907B1 (no)
PT (1) PT814782E (no)
RU (1) RU2142790C1 (no)
SI (1) SI0814782T1 (no)
SK (1) SK282991B6 (no)
TW (1) TW436294B (no)
UA (1) UA29513C2 (no)
WO (1) WO1997023200A1 (no)
ZA (1) ZA9610792B (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
AU2866400A (en) * 1999-03-08 2000-09-28 Merck & Co., Inc. Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
EP1036563A1 (en) * 1999-03-08 2000-09-20 MERCK & CO. INC. Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
JP4048780B2 (ja) 1999-12-13 2008-02-20 株式会社豊田中央研究所 キノリン誘導体化合物及び有機電界発光素子
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
JP2004501121A (ja) 2000-06-09 2004-01-15 エルイーケー　ファーマシューティカルズ　ディー．ディー． 安定した医薬効果を有する合成物、及びそれを含む医薬製剤
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
JP4630065B2 (ja) * 2002-09-20 2011-02-09 興和株式会社 外用剤
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
AU2004308332B2 (en) 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
WO2005063294A1 (ja) 2003-12-30 2005-07-14 Kowa Company, Ltd. γ-セクレターゼ複合体形成阻害剤
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
WO2005079846A1 (ja) 2004-02-25 2005-09-01 Kowa Company, Ltd. Racタンパク質の核内移行促進剤及びそのスクリーニング方法
WO2005079847A1 (ja) 2004-02-25 2005-09-01 Kowa Company, Ltd. Cdc42タンパク質の核内移行促進剤及びそのスクリーニング方法
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2006204038A1 (en) 2005-01-06 2006-07-13 Merck & Co., Inc. Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
EP1726962A1 (en) * 2005-05-24 2006-11-29 Leiden University Medical Center Apolipoprotein E plasma levels for monitoring and reducing the risk of cardiovascular disease
CN101103983B (zh) * 2006-07-14 2012-09-26 海南盛科生命科学研究院 一种用碱试剂稳定的含匹伐他汀钙的药用组合物及制备工艺
AU2008266960A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
EP2626069A4 (en) 2010-10-06 2014-03-19 Univ Tokyo A MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF A DERY LYMPH
WO2012097744A1 (en) 2011-01-20 2012-07-26 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
JP5988963B2 (ja) * 2011-04-12 2016-09-07 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
US9487506B2 (en) 2011-04-13 2016-11-08 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
WO2012153181A1 (en) 2011-05-11 2012-11-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
CN102861018A (zh) * 2011-07-05 2013-01-09 南京长澳医药科技有限公司 一种匹伐他汀钙制剂及其制备工艺
JP5809467B2 (ja) * 2011-07-12 2015-11-11 エルメッド エーザイ株式会社 ピタバスタチン含有組成物及びその製造方法
JP5844574B2 (ja) * 2011-08-10 2016-01-20 共和薬品工業株式会社 ピタバスタチンを含有する安定化された薬物組成物
US9505730B2 (en) 2011-10-13 2016-11-29 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
EP3124017A1 (en) 2012-08-08 2017-02-01 Kowa Company, Ltd. Pharmaceutical composition comprising pitavastatine
CN102885797A (zh) * 2012-10-29 2013-01-23 福州海王福药制药有限公司 一种含匹伐他汀钙的组合物及其制备方法和应用
WO2015066490A1 (en) 2013-10-31 2015-05-07 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
US10392381B2 (en) 2014-07-18 2019-08-27 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
CN105343008A (zh) * 2015-12-15 2016-02-24 青岛华之草医药科技有限公司 一种匹伐他汀钙组合物
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
CA1336714C (en) * 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
JP3528186B2 (ja) * 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them

Also Published As

Publication number Publication date
KR19980702370A (ko) 1998-07-15
NO2011006I2 (no) 2012-10-01
WO1997023200A1 (en) 1997-07-03
CN1189098A (zh) 1998-07-29
JP3276962B2 (ja) 2002-04-22
NO2011006I1 (no) 2011-06-06
FR11C0007I1 (no) 2011-04-22
CA2213608A1 (en) 1997-07-03
KR100348842B1 (ko) 2002-12-31
ATE228354T1 (de) 2002-12-15
UA29513C2 (uk) 2000-11-15
FR11C0007I2 (fr) 2012-03-16
SK282991B6 (sk) 2003-01-09
CN1137684C (zh) 2004-02-11
DK0814782T3 (da) 2002-12-16
PT814782E (pt) 2003-04-30
IL121565A0 (en) 1998-02-08
AU725622B2 (en) 2000-10-19
CA2213608C (en) 2003-07-08
PL321868A1 (en) 1997-12-22
CZ268197A3 (cs) 1998-05-13
RU2142790C1 (ru) 1999-12-20
JPH11503763A (ja) 1999-03-30
SI0814782T1 (en) 2003-04-30
DE69625046D1 (de) 2003-01-09
EP0814782B1 (en) 2002-11-27
CZ288545B6 (cs) 2001-07-11
DE122011000014I1 (de) 2011-11-03
NZ324446A (en) 1999-08-30
DE69625046T2 (de) 2003-04-10
TW436294B (en) 2001-05-28
SK116097A3 (en) 1998-03-04
ZA9610792B (en) 1997-07-09
MX9706389A (es) 1998-08-30
AU1171597A (en) 1997-07-17
HUP9903536A2 (hu) 2000-03-28
HUP9903536A3 (en) 2001-06-28
EP0814782A1 (en) 1998-01-07
HU227798B1 (en) 2012-03-28
IL121565A (en) 2002-02-10
ES2183023T3 (es) 2003-03-16
NO973814D0 (no) 1997-08-19
NO316724B1 (no) 2004-04-19
PL186907B1 (pl) 2004-03-31

Similar Documents

Publication Publication Date Title
NO973814L (no) Basisk stabilisert sammensetning av HMG-CoA-reduktase inhibitor
RU92004564A (ru) Фармацевтические композиции и способ их получения
CA2085037A1 (en) Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor compound
UA77156C2 (en) Pharmaceutical composition containing a hmg coa reductase inhibitor
TNSN01108A1 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
AU5683296A (en) N-benzylindol-3-yl propanic acid derivatives as cyclooxygena se-2 inhibitors
AU2524692A (en) Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
HU9602229D0 (en) Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo[c]azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace
CA2391076A1 (en) Solutions containing epinastin
AU4320685A (en) 1-cyclopropyl-1,4-dihydro-4-oxo-3-quinoline carboxylic acid derivatives
IS6654A (is) Stöðugt gabapentín með pH innan stýrðra marka
WO2002000615A3 (en) Process for the isolation of lovastatin
AU2001272761A1 (en) Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products
IT1237792B (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
EA199900352A1 (ru) Композиции жидкого алендроната
FI951378A (fi) N-asetyyli-neuramiinihapon johdannaisten synteesi
WO2002076376A3 (en) A stable pharmaceutical composition of pravastatin
DE69030044D1 (de) Tetrazolessigsäurederivate mit Aldosereduktase inhibierender Wirkung
KR910014122A (ko) 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
AU1190997A (en) Use of hetarylacetic acid derivatives as leukotriene inhibitors
EE9400258A (et) Kombinatsioonpreparaadid p- hüdroksübensoehappe derivaadi ja HMG- CoA- reduktaasi pärssija sisaldusega
ZA927209B (en) Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE.
AU2002306235A1 (en) Carboxylic acid derivative and medicine comprising salt or ester of the same

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: LIVAZO; NAT. REG. NO/DATE: 10-7330 20101116; FIRST REG. NO/DATE: 300468 20101124

Spc suppl protection certif: 2011006

Filing date: 20110504

CREP Change of representative

Representative=s name: ACAPO AS, POSTBOKS 1880 NORDNES, 5817

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: LIVAZO; NAT. REG. NO/DATE: 10-7330 20101116; FIRST REG. NO/DATE: 300468 20101124

Spc suppl protection certif: 2011006

Filing date: 20110504

Extension date: 20211220

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2011006